Great to see @anzuptrials.bsky.social #ENZAMET study feature in 2 more posters #ASCO25 by Prof Louise Emmett and Prof Lisa Horvath (pictured with co-author Prof Anthony Joshua) #ChrisSweeney @profiand.bsky.social #NHMRCCTC @cancertrialsie.bsky.social @cctg.bsky.social @astellaspharma.bsky.social

#ENZAMET @anzuptrials.bsky.social #NHMRCTrialsCentre #ASCO25
✅ 50% survival at 8yr vs 40% - sustained, all subgroups
✅ non- #ProstateCancer #pcsm deaths same in both arms: removes doubts of long term safety and benefit re competing causes of death
✅ undetectable PSA is good; more likely with enza

Great to see @anzuptrials.bsky.social #ENZAMET 8-year outcomes poster feature at #ASCO25 presented by Alison Zhang #ChrisSweeney @profiand.bsky.social #NHMRCCTC @cancertrialsie.bsky.social @cctg.bsky.social @astellaspharma.bsky.social #CancerAustralia

Enzalutamide with standard first-line therapy for metastatic hormone-sensitive prostate cancer: a plain language summary of the ENZAMET trial (ANZUP 1304) Published in Future Oncology (Ahead of Print, 2025)

Great to see @anzuptrials.bsky.social #ENZAMET study feature in two Plain Language Summaries this month: bit.ly/4jpkxeh & bit.ly/40qTC9e #ProfChristopherSweeney @profiand.bsky.social #NHMRCCTC @cancertrialsie.bsky.social @cctg.bsky.social @astellaspharma.bsky.social #CancerAustralia

Good to see @anzuptrials.bsky.social #ENZAMET trial getting a mention during the #ChristopherSweeney talk and panel discussion at the ACTA Clinical Trials and Registries Symposium ‘Harnessing the value of clinic-genomic data from multiple phase 3 prostate cancer trials’ @profiand.bsky.social

Great to see Yu Yang Soon presenting a poster at ACTA Clinical Trials and Registries Symposium featuring @anzuptrials.bsky.social #ENZAMET study – ‘Estimating Treatment Effects After a Positive Initial Interim Analysis: Challenges and Considerations’ #ChristopherSweeney @profiand.bsky.social